Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
12.28
+0.58 (4.96%)
At close: Feb 21, 2025, 4:00 PM
12.48
+0.20 (1.63%)
After-hours: Feb 21, 2025, 6:06 PM EST
Alvotech Employees
Alvotech had 999 employees as of December 31, 2023. The number of employees increased by 82 or 8.94% compared to the previous year.
Employees
999
Change (1Y)
82
Growth (1Y)
8.94%
Revenue / Employee
$394,313
Profits / Employee
-$441,896
Market Cap
3.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 999 | 82 | 8.94% |
| Dec 31, 2022 | 917 | 133 | 16.96% |
| Dec 31, 2021 | 784 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ALVO News
- 1 day ago - Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - Reuters
- 1 day ago - Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. - GlobeNewsWire
- 4 days ago - FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea - Investopedia
- 4 days ago - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire
- 26 days ago - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) - GlobeNewsWire
- 2 months ago - Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - GlobeNewsWire
- 3 months ago - Alvotech's Position In The Coming Biosimilar Gold Rush - Seeking Alpha
- 3 months ago - Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors - Business Wire